The gut-liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance?

Hepatology

Volumn 49, Issue 6, 2009, Pages 1790-1792

  Vanni, Ester ^a   Bugianesi, Elisabetta ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; EDETIC ACID; ENDOTOXIN; FRUCTOSE OLIGOSACCHARIDE; OCCLUDIN; PROTEIN ZO1; SHORT CHAIN FATTY ACID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL OVERGROWTH; BREATH ANALYSIS; DIABETES MELLITUS; DIETARY FIBER; DIETARY INTAKE; DISEASE COURSE; EDITORIAL; ENDOTOXEMIA; GENOTYPE; HEPATITIS; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INTESTINAL DYSMOTILITY; INTESTINE ABSORPTION; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; JEJUNOILEAL BYPASS; LIPOGENESIS; LIVER FIBROSIS; LIVER INJURY; METABOLIC SYNDROME X; METABOLISM; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRIENT AVAILABILITY; NUTRIENT UPTAKE; OBESITY; PATHOGENESIS; PORTAL VEIN BLOOD FLOW; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; STEATOSIS; TIGHT JUNCTION;

ANIMALS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; INTESTINE, SMALL; LIVER;

EID: 68949086365     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23036     Document Type: Editorial

References (22)

1. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittman BE. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008;83:460-469.
2. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: Lumen-liver interactions and possible role for probiotics. J Hepatol 2003;38:681-687.
3. Brun P, Catsagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G, et al. Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007;292:G518-G525.
4. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-211.
5. Sajjad A, Mottershead M, Syn WK, Jones R, Smith S, Nwokolo CU. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005;22:291-299.
6. Sabaté JM, Jouët P, Harnois F, Mechler C, Msika S, Grossin M, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: A contributor to severe hepatic steatosis. Obes Surg 2008;18:371.
7. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in non-alcoholic fatty liver disease (NAFLD). HEPATOLOGY 2009; doi:10.1002/hep.22848.
8. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997;94:2557-2562.
9. Cuoco L, Montalto M, Jorizzo RA, Santarelli L, Arancio F, Cammarota G, et al. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology 2002;49:1582-1586.
10. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004;101:15718-15723.
11. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005;102: 11070-11075.
12. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity fro energy harvest. Nature 2006;444:1027-1031.
13. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature 2006;444:1022-1023.
14. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-1772.
15. Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. J Hepatol 2008;48:983-992.
16. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC, et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008;87:1219-1223.
17. Kaput J, Dawson K. Complexity of type 2 diabetes mellitus data sets emerging from nutrigenomic research: A case for dimensionality reduction? Mutat Res 2007;622:19-32.
18. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-3026.
19. Cani PD, Bibiloni R, Knauf C, Waget A, Meyrinck A, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470-1481.
20. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007;50:2374-2383.
21. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. HEPATOLOGY 2003;37:343-350.
22. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008;22:2416-2426.